Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13796417 | 0.81 | ATM (0.50) | PDPK1ATML3MBTL1CYP1A2CYP2A6 | |
| SCHEMBL3633864 | 0.78 | ATM (0.51) | PDPK1ATML3MBTL1CYP1A2CYP2A6 | |
| SCHEMBL6705337 | 0.78 | ATM (0.47) | PDPK1ATML3MBTL1CYP1A2CYP2A6 | |
| SCHEMBL15577710 | 0.76 | MAPK1 (0.46) | PDPK1ATML3MBTL1CYP1A2CYP2A6 | |
| SCHEMBL3636909 | 0.75 | CYP1A2 (0.46) | PDPK1ATML3MBTL1CYP1A2CYP2A6 | |
| SCHEMBL3634029 | 0.74 | ATM (0.47) | PDPK1ATML3MBTL1CYP1A2CYP2A6 | |
| SCHEMBL2314292 | 0.73 | EGLN1 (0.48) | ATML3MBTL1CYP1A2 | |
| SCHEMBL523447 | 0.72 | MAOA (0.64) | MAOAMAOBLTA4HTAAR1NPC1 | |
| SCHEMBL31613919 | 0.72 | TACR1 (0.47) | PDPK1ATML3MBTL1CYP1A2CYP2A6 | |
| SCHEMBL3121339 | 0.72 | HTR2B (0.50) | PDPK1ATML3MBTL1LTA4HCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1867654-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | NAGOYA IND SCIENCE RES INST (JP) | 2014-06-11 | — | — | EP | disclosed |
| US-8212037-B2 | Process for production of optically active quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA | 2009-08-27 | — | — | US | disclosed |
| EP-1867654-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | Nagoya Industrial Science Research Institute (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | NQO2, ADH7, MRPL21 | MAOA 739/4885MAOB 1369/4885PDPK1 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.